Abciximab
Phenylbutazone may increase the anticoagulant activities of Abciximab.
Abiraterone
The metabolism of Phenylbutazone can be decreased when combined with Abiraterone.
Acebutolol
Phenylbutazone may decrease the antihypertensive activities of Acebutolol.
Advertisement
Aceclofenac
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Aceclofenac.
Acemetacin
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Acemetacin.
Acenocoumarol
Phenylbutazone may increase the anticoagulant activities of Acenocoumarol.
Advertisement
Acetaminophen
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Acetaminophen.
Acetyl Sulfisoxazole
The metabolism of Phenylbutazone can be decreased when combined with Acetyl sulfisoxazole.
Adapalene
The risk or severity of adverse effects can be increased when Adapalene is combined with Phenylbutazone.
Advertisement
Alclometasone
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Alclometasone.
Aldosterone
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Aldosterone.
Alendronate
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Alendronic acid.
Alendronic acid
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Alendronic acid.
Aliskiren
Phenylbutazone may decrease the antihypertensive activities of Aliskiren.
Alminoprofen
The risk or severity of adverse effects can be increased when Alminoprofen is combined with Phenylbutazone.
Alprenolol
Phenylbutazone may decrease the antihypertensive activities of Alprenolol.
Alprostadil
The therapeutic efficacy of Alprostadil can be decreased when used in combination with Phenylbutazone.
Amcinonide
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Amcinonide.
Amikacin
Phenylbutazone may decrease the excretion rate of Amikacin which could result in a higher serum level.
Amiloride
Phenylbutazone may decrease the antihypertensive activities of Amiloride.
Aminosalicylic Acid
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Aminosalicylic Acid.
Amiodarone
The metabolism of Phenylbutazone can be decreased when combined with Amiodarone.
Ancrod
Phenylbutazone may increase the anticoagulant activities of Ancrod.
Androstenedione
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Androstenedione.
Anhydrous Tacrolimus
Phenylbutazone may increase the nephrotoxic activities of Tacrolimus.
Antipyrine
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Antipyrine.
Antithrombin III
Phenylbutazone may increase the anticoagulant activities of Antithrombin III human.
Antithrombin III, Human
Phenylbutazone may increase the anticoagulant activities of Antithrombin III human.
Apalutamide
The serum concentration of Phenylbutazone can be decreased when it is combined with Apalutamide.
Apazone
The risk or severity of adverse effects can be increased when Azapropazone is combined with Phenylbutazone.
Apixaban
Phenylbutazone may increase the anticoagulant activities of Apixaban.
Apremilast
The risk or severity of adverse effects can be increased when Apremilast is combined with Phenylbutazone.
Aprepitant
The metabolism of Phenylbutazone can be increased when combined with Aprepitant.
Arbekacin
Phenylbutazone may decrease the excretion rate of Arbekacin which could result in a higher serum level.
Ardeparin
Phenylbutazone may increase the anticoagulant activities of Ardeparin.
Argatroban
Phenylbutazone may increase the anticoagulant activities of Argatroban.
Argatroban Anhydrous
Phenylbutazone may increase the anticoagulant activities of Argatroban.
Aripiprazole
The serum concentration of Aripiprazole can be decreased when it is combined with Phenylbutazone.
Asenapine
Phenylbutazone may decrease the antihypertensive activities of Asenapine.
Asian ginseng extract
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Ginseng.
Asunaprevir
The serum concentration of Asunaprevir can be decreased when it is combined with Phenylbutazone.
Atenolol
Phenylbutazone may decrease the antihypertensive activities of Atenolol.
Azelastine
The risk or severity of adverse effects can be increased when Azelastine is combined with Phenylbutazone.
azficel-T
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Azficel-T.
Azilsartan
The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Phenylbutazone.
Azilsartan kamedoxomil
The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Phenylbutazone.
Azilsartan Medoxomil
The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Phenylbutazone.
Azosemide
The therapeutic efficacy of Azosemide can be decreased when used in combination with Phenylbutazone.
Balsalazide
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Balsalazide.
Bazedoxifene
Phenylbutazone may increase the thrombogenic activities of Bazedoxifene.
Becaplermin
Phenylbutazone may increase the anticoagulant activities of Becaplermin.
Beclomethasone Dipropionate
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Beclomethasone dipropionate.
Benazepril
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Benazepril.
Bendroflumethiazide
The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Phenylbutazone.
Benzthiazide
The therapeutic efficacy of Benzthiazide can be decreased when used in combination with Phenylbutazone.
Benzydamine
The risk or severity of adverse effects can be increased when Benzydamine is combined with Phenylbutazone.
Betamethasone
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Betamethasone.
Betaxolol
Phenylbutazone may decrease the antihypertensive activities of Betaxolol.
Betrixaban
The risk or severity of bleeding can be increased when Betrixaban is combined with Phenylbutazone.
Bimatoprost
The therapeutic efficacy of Bimatoprost can be decreased when used in combination with Phenylbutazone.
Bisoprolol
Phenylbutazone may decrease the antihypertensive activities of Bisoprolol.
Bivalirudin
Phenylbutazone may increase the anticoagulant activities of Bivalirudin.
Bopindolol
Phenylbutazone may decrease the antihypertensive activities of Bopindolol.
Bromfenac
The risk or severity of adverse effects can be increased when Bromfenac is combined with Phenylbutazone.
Budesonide
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Budesonide.
Bufexamac
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Bufexamac.
Bumetanide
The therapeutic efficacy of Bumetanide can be decreased when used in combination with Phenylbutazone.
Bupranolol
Phenylbutazone may decrease the antihypertensive activities of Bupranolol.
Candesartan
The risk or severity of adverse effects can be increased when Candesartan is combined with Phenylbutazone.
Candesartan Cilexetil
The risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Phenylbutazone.
Capecitabine
The metabolism of Phenylbutazone can be decreased when combined with Capecitabine.
Capsaicin
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Capsaicin.
Captopril
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Captopril.
Carbamazepine
The metabolism of Phenylbutazone can be increased when combined with Carbamazepine.
Carboprost
The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Phenylbutazone.
Carboprost Tromethamine
The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Phenylbutazone.
Carprofen
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Carprofen.
Carteolol
Phenylbutazone may decrease the antihypertensive activities of Carteolol.
Carvedilol
Phenylbutazone may decrease the antihypertensive activities of Carvedilol.
Celecoxib
The risk or severity of adverse effects can be increased when Celecoxib is combined with Phenylbutazone.
Celiprolol
Phenylbutazone may decrease the antihypertensive activities of Celiprolol.
Ceritinib
The serum concentration of Phenylbutazone can be increased when it is combined with Ceritinib.
Certoparin
Phenylbutazone may increase the anticoagulant activities of Certoparin.
Chloroquine
The risk or severity of adverse effects can be increased when Chloroquine is combined with Phenylbutazone.
Chlorothiazide
The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Phenylbutazone.
Chlorotrianisene
Phenylbutazone may increase the thrombogenic activities of Chlorotrianisene.
Chlorphenesin
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Chlorphenesin.
Chlorthalidone
The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Phenylbutazone.
Cholecalciferol
The metabolism of Phenylbutazone can be decreased when combined with Cholecalciferol.
Cholestyramine Resin
Cholestyramine can cause a decrease in the absorption of Phenylbutazone resulting in a reduced serum concentration and potentially a decrease in efficacy.
Choline Magnesium Trisalicyclate
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Choline magnesium trisalicylate.
Ciclesonide
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Ciclesonide.
Cilazapril
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Cilazapril.
Cinoxacin
Phenylbutazone may increase the neuroexcitatory activities of Cinoxacin.
Ciprofloxacin
Phenylbutazone may increase the neuroexcitatory activities of Ciprofloxacin.
Cisplatin
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Cisplatin.
Citalopram
Citalopram may increase the antiplatelet activities of Phenylbutazone.
Citric Acid
Phenylbutazone may increase the anticoagulant activities of Citric Acid.
Citric Acid, Anhydrous
Phenylbutazone may increase the anticoagulant activities of Citric Acid.
Clobetasol
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Clobetasol.
Clobetasol Propionate
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Clobetasol propionate.
Clobetasone
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Clobetasone.
Clocortolone
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Clocortolone.
Clodronic Acid
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Clodronic Acid.
Clonixin
The risk or severity of adverse effects can be increased when Clonixin is combined with Phenylbutazone.
Clotrimazole
The metabolism of Phenylbutazone can be decreased when combined with Clotrimazole.
Colesevelam
Colesevelam can cause a decrease in the absorption of Phenylbutazone resulting in a reduced serum concentration and potentially a decrease in efficacy.
Colestipol
Colestipol can cause a decrease in the absorption of Phenylbutazone resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cortisone Acetate
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Cortisone acetate.
Crisaborole
The metabolism of Phenylbutazone can be decreased when combined with Crisaborole.
Curcumin
The risk or severity of adverse effects can be increased when Curcumin is combined with Phenylbutazone.
Cyclopenthiazide
The therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Phenylbutazone.
Cyclosporine
Phenylbutazone may increase the nephrotoxic activities of Cyclosporine.
Dabigatran Etexilate
Phenylbutazone may increase the anticoagulant activities of Dabigatran etexilate.
Dabrafenib
The serum concentration of Phenylbutazone can be decreased when it is combined with Dabrafenib.
Dalteparin
Phenylbutazone may increase the anticoagulant activities of Dalteparin.
Danaparoid
Phenylbutazone may increase the anticoagulant activities of Danaparoid.
Deferasirox
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Deferasirox.
Deflazacort
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Deflazacort.
Delavirdine
The metabolism of Phenylbutazone can be decreased when combined with Delavirdine.
Desipramine
Phenylbutazone may decrease the antihypertensive activities of Desipramine.
Desirudin
Phenylbutazone may increase the anticoagulant activities of Desirudin.
Desmopressin
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Desmopressin.
Desonide
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Desonide.
Desoximetasone
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Desoximetasone.
Desoxycorticosterone acetate
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Desoxycorticosterone acetate.
Desoxycorticosterone Pivalate
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Desoxycorticosterone Pivalate.
Desvenlafaxine
Desvenlafaxine may increase the antiplatelet activities of Phenylbutazone.
Dexamethasone
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Dexamethasone.
Dexketoprofen
The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Phenylbutazone.
Dextran
Phenylbutazone may increase the anticoagulant activities of Dextran.
Diclofenac
The risk or severity of adverse effects can be increased when Diclofenac is combined with Phenylbutazone.
Dicumarol
Phenylbutazone may increase the anticoagulant activities of Dicoumarol.
Dienestrol
Phenylbutazone may increase the thrombogenic activities of Dienestrol.
Diethylstilbestrol
Phenylbutazone may increase the thrombogenic activities of Diethylstilbestrol.
Diflorasone
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Diflorasone.
Diflucortolone
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Difluocortolone.
Diflunisal
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Diflunisal.
Difluprednate
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Difluprednate.
Digoxin
The serum concentration of Digoxin can be increased when it is combined with Phenylbutazone.
Dihydrostreptomycin
Phenylbutazone may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.
Dinoprost
The therapeutic efficacy of Dinoprost can be decreased when used in combination with Phenylbutazone.
Dinoprost Tromethamine
The therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Phenylbutazone.
Dinoprostone
The therapeutic efficacy of Dinoprostone can be decreased when used in combination with Phenylbutazone.
Dipyrone
The risk or severity of adverse effects can be increased when Metamizole is combined with Phenylbutazone.
Dothiepin
The metabolism of Phenylbutazone can be decreased when combined with Dosulepin.
Drospirenone
Phenylbutazone may increase the hyperkalemic activities of Drospirenone.
Droxicam
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Droxicam.
Duloxetine
Duloxetine may increase the antiplatelet activities of Phenylbutazone.
Edetic Acid
Phenylbutazone may increase the anticoagulant activities of Edetic Acid.
Edoxaban
Phenylbutazone may increase the anticoagulant activities of Edoxaban.
Efavirenz
The metabolism of Phenylbutazone can be decreased when combined with Efavirenz.
Eicosapentaenoic Acid
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Icosapent.
Enalapril
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Enalapril.
Enalaprilat
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Enalaprilat.
Enalaprilat Anhydrous
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Enalaprilat.
Enoxacin
Phenylbutazone may increase the neuroexcitatory activities of Enoxacin.
Enoxaparin
Phenylbutazone may increase the anticoagulant activities of Enoxaparin.
Enoxaparin sodium
Phenylbutazone may increase the anticoagulant activities of Enoxaparin.
Eplerenone
Phenylbutazone may decrease the antihypertensive activities of Eplerenone.
Epoprostenol
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Phenylbutazone.
Eprosartan
The risk or severity of adverse effects can be increased when Eprosartan is combined with Phenylbutazone.
Equol, (-)-
Phenylbutazone may increase the thrombogenic activities of Equol.
Escitalopram
Escitalopram may increase the antiplatelet activities of Phenylbutazone.
Esmolol
Phenylbutazone may decrease the antihypertensive activities of Esmolol.
Estradiol
Phenylbutazone may increase the thrombogenic activities of Estradiol.
Estradiol acetate
Phenylbutazone may increase the thrombogenic activities of Estradiol acetate.
Estradiol Cypionate
Phenylbutazone may increase the thrombogenic activities of Estradiol cypionate.
Estradiol Valerate
Phenylbutazone may increase the thrombogenic activities of Estradiol valerate.
Estriol
Phenylbutazone may increase the thrombogenic activities of Estriol.
Estrogens, Conjugated (USP)
Phenylbutazone may increase the thrombogenic activities of Conjugated estrogens.
Estrogens, Esterified (USP)
Phenylbutazone may increase the thrombogenic activities of Estrogens, esterified.
Estrone
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Estrone.
Etanercept
The risk or severity of adverse effects can be increased when Etanercept is combined with Phenylbutazone.
Ethacrynate
The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Phenylbutazone.
Ethacrynic Acid
The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Phenylbutazone.
Ethinyl Estradiol
Phenylbutazone may increase the thrombogenic activities of Ethinyl Estradiol.
Ethylenediaminetetraacetate
Phenylbutazone may increase the anticoagulant activities of Edetic Acid.
Etidronate
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Etidronic acid.
Etidronic Acid
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Etidronic acid.
Etodolac
The risk or severity of adverse effects can be increased when Etodolac is combined with Phenylbutazone.
Etofenamate
The risk or severity of adverse effects can be increased when Etofenamate is combined with Phenylbutazone.
Etoricoxib
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Etoricoxib.
Etravirine
The metabolism of Phenylbutazone can be decreased when combined with Etravirine.
Evening primrose oil
The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Phenylbutazone.
Felbinac
The risk or severity of adverse effects can be increased when Felbinac is combined with Phenylbutazone.
Fenbufen
The risk or severity of adverse effects can be increased when Fenbufen is combined with Phenylbutazone.
Fenoprofen
The risk or severity of adverse effects can be increased when Fenoprofen is combined with Phenylbutazone.
Ferulic Acid
The risk or severity of adverse effects can be increased when Ferulic acid is combined with Phenylbutazone.
Fish Oils
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Fish oil.
Fleroxacin
Phenylbutazone may increase the neuroexcitatory activities of Fleroxacin.
Floctafenine
The risk or severity of adverse effects can be increased when Floctafenine is combined with Phenylbutazone.
Floxuridine
The metabolism of Phenylbutazone can be decreased when combined with Floxuridine.
Fluconazole
The metabolism of Phenylbutazone can be decreased when combined with Fluconazole.
Fludrocortisone
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Fludrocortisone.
Fluindione
Phenylbutazone may increase the anticoagulant activities of Fluindione.
Flumequine
Phenylbutazone may increase the neuroexcitatory activities of Flumequine.
Flumethasone
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Flumethasone.
Flunisolide
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Flunisolide.
Flunisolide Anhydrous (obsolete)
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Flunisolide.
Fluocinolone Acetonide
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Fluocinolone Acetonide.
Fluocinonide
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Fluocinonide.
Fluocortolone
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Fluocortolone.
Fluorometholone
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Fluorometholone.
Fluorouracil
The metabolism of Phenylbutazone can be decreased when combined with Fluorouracil.
Fluoxetine
Fluoxetine may increase the antiplatelet activities of Phenylbutazone.
FLUPREDNIDENE
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Fluprednidene.
Fluprednisolone
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Fluprednisolone.
Flurandrenolide
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Flurandrenolide.
Flurbiprofen
The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Phenylbutazone.
Fluticasone
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Fluticasone.
Fluticasone Furoate
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Fluticasone furoate.
Fluticasone propionate
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Fluticasone propionate.
Fluvastatin
The metabolism of Phenylbutazone can be decreased when combined with Fluvastatin.
Fluvoxamine
The metabolism of Phenylbutazone can be decreased when combined with Fluvoxamine.
Folate
The therapeutic efficacy of Folic Acid can be decreased when used in combination with Phenylbutazone.
Folic Acid
The therapeutic efficacy of Folic Acid can be decreased when used in combination with Phenylbutazone.
Fondaparinux sodium
Phenylbutazone may increase the anticoagulant activities of Fondaparinux sodium.
Formestane
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Formestane.
Fosinopril
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Fosinopril.
Fosphenytoin
The metabolism of Phenylbutazone can be increased when combined with Fosphenytoin.
Framycetin
Phenylbutazone may decrease the excretion rate of Framycetin which could result in a higher serum level.
Furosemide
The therapeutic efficacy of Furosemide can be decreased when used in combination with Phenylbutazone.
Gatifloxacin
Phenylbutazone may increase the neuroexcitatory activities of Gatifloxacin.
Gatifloxacin Anhydrous
Phenylbutazone may increase the neuroexcitatory activities of Gatifloxacin.
Gemeprost
The therapeutic efficacy of Gemeprost can be decreased when used in combination with Phenylbutazone.
Gemfibrozil
The metabolism of Phenylbutazone can be decreased when combined with Gemfibrozil.
Gemifloxacin
Phenylbutazone may increase the neuroexcitatory activities of Gemifloxacin.
Gemifloxacin Mesylate
Phenylbutazone may increase the neuroexcitatory activities of Gemifloxacin.
Genistein
Phenylbutazone may increase the thrombogenic activities of Genistein.
Gentamicin
Phenylbutazone may decrease the excretion rate of Gentamicin which could result in a higher serum level.
Ginseng Preparation
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Ginseng.
Grepafloxacin
Phenylbutazone may increase the neuroexcitatory activities of Grepafloxacin.
Halcinonide
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Halcinonide.
Halobetasol
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Ulobetasol.
Haloperidol
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Haloperidol.
Heparin
Phenylbutazone may increase the anticoagulant activities of Heparin.
Hydralazine
Phenylbutazone may decrease the antihypertensive activities of Hydralazine.
Hydrochlorothiazide
The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Phenylbutazone.
Hydrocortisone
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Hydrocortisone.
Hydroflumethiazide
The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Phenylbutazone.
Ibandronate
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Ibandronate.
Ibandronic Acid
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Ibandronate.
Ibuprofen
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Ibuprofen.
Icatibant
The risk or severity of adverse effects can be increased when Icatibant is combined with Phenylbutazone.
Iloprost
The therapeutic efficacy of Iloprost can be decreased when used in combination with Phenylbutazone.
Imidapril
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Imidapril.
Indapamide
The therapeutic efficacy of Indapamide can be decreased when used in combination with Phenylbutazone.
Indinavir
The metabolism of Phenylbutazone can be decreased when combined with Indinavir.
INDINAVIR ANHYDROUS
The metabolism of Phenylbutazone can be decreased when combined with Indinavir.
Indobufen
The risk or severity of adverse effects can be increased when Indobufen is combined with Phenylbutazone.
Indomethacin
The risk or severity of adverse effects can be increased when Indomethacin is combined with Phenylbutazone.
Irbesartan
The metabolism of Phenylbutazone can be decreased when combined with Irbesartan.
Kanamycin
Phenylbutazone may decrease the excretion rate of Kanamycin which could result in a higher serum level.
kanamycin A
Phenylbutazone may decrease the excretion rate of Kanamycin which could result in a higher serum level.
Kebuzone
The risk or severity of adverse effects can be increased when Kebuzone is combined with Phenylbutazone.
Ketoconazole
The metabolism of Phenylbutazone can be decreased when combined with Ketoconazole.
Ketoprofen
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Ketoprofen.
Ketorolac
The risk or severity of adverse effects can be increased when Ketorolac is combined with Phenylbutazone.
Korean ginseng preparation
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Ginseng.
KOREAN GINSENG ROOT
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Ginseng.
Korean Ginseng Root Extract
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Ginseng.
Labetalol
Phenylbutazone may decrease the antihypertensive activities of Labetalol.
Latanoprost
The therapeutic efficacy of Latanoprost can be decreased when used in combination with Phenylbutazone.
Latanoprostene Bunod
The therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Phenylbutazone.
Leflunomide
The risk or severity of adverse effects can be increased when Leflunomide is combined with Phenylbutazone.
Lepirudin
Phenylbutazone may increase the anticoagulant activities of Lepirudin.
Levobetaxolol
Phenylbutazone may decrease the antihypertensive activities of Levobetaxolol.
Levobunolol
Phenylbutazone may decrease the antihypertensive activities of Levobunolol.
Levofloxacin
Phenylbutazone may increase the neuroexcitatory activities of Levofloxacin.
Levofloxacin Anhydrous
Phenylbutazone may increase the neuroexcitatory activities of Levofloxacin.
Levomilnacipran
Levomilnacipran may increase the antiplatelet activities of Phenylbutazone.
Limonene, (+)-
The risk or severity of adverse effects can be increased when (4R)-limonene is combined with Phenylbutazone.
Lisinopril
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Lisinopril.
Lisinopril Anhydrous
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Lisinopril.
Lithium
The serum concentration of Lithium can be increased when it is combined with Phenylbutazone.
Lithium Cation
The serum concentration of Lithium can be increased when it is combined with Phenylbutazone.
Lomefloxacin
Phenylbutazone may increase the neuroexcitatory activities of Lomefloxacin.
Lornoxicam
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Lornoxicam.
Losartan
The metabolism of Phenylbutazone can be decreased when combined with Losartan.
Loteprednol
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Loteprednol.
Lovastatin
The metabolism of Phenylbutazone can be decreased when combined with Lovastatin.
Loxoprofen
The risk or severity of adverse effects can be increased when Loxoprofen is combined with Phenylbutazone.
Lubiprostone
The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Phenylbutazone.
Lumacaftor
The serum concentration of Phenylbutazone can be decreased when it is combined with Lumacaftor.
Magnesium Salicylate
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Magnesium salicylate.
Manidipine
The metabolism of Phenylbutazone can be decreased when combined with Manidipine.
Masoprocol
The risk or severity of adverse effects can be increased when Masoprocol is combined with Phenylbutazone.
Meclofenamate
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Meclofenamic acid.
Meclofenamic Acid
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Meclofenamic acid.
Medrogestone
The serum concentration of Medrogestone can be decreased when it is combined with Phenylbutazone.
Medronate
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Technetium Tc-99m medronate.
Medrysone
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Medrysone.
Mefenamic Acid
The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Phenylbutazone.
Meloxicam
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Meloxicam.
Mepindolol
Phenylbutazone may decrease the antihypertensive activities of Mepindolol.
Mesalamine
The risk or severity of adverse effects can be increased when Mesalazine is combined with Phenylbutazone.
Mestranol
Phenylbutazone may increase the thrombogenic activities of Mestranol.
Methotrexate
The serum concentration of Methotrexate can be increased when it is combined with Phenylbutazone.
Methyclothiazide
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Phenylbutazone.
Methylprednisolone
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Methylprednisolone.
Metipranolol
Phenylbutazone may decrease the antihypertensive activities of Metipranolol.
Metolazone
The therapeutic efficacy of Metolazone can be decreased when used in combination with Phenylbutazone.
Metoprolol
Phenylbutazone may decrease the antihypertensive activities of Metoprolol.
Midostaurin
The metabolism of Phenylbutazone can be decreased when combined with Midostaurin.
Mifepristone
The serum concentration of Phenylbutazone can be increased when it is combined with Mifepristone.
Milnacipran
Milnacipran may increase the antiplatelet activities of Phenylbutazone.
Misoprostol
The therapeutic efficacy of Misoprostol can be decreased when used in combination with Phenylbutazone.
Moexipril
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Moexipril.
Mometasone
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Mometasone.
Morniflumate
The risk or severity of adverse effects can be increased when Morniflumate is combined with Phenylbutazone.
Moxifloxacin
Phenylbutazone may increase the neuroexcitatory activities of Moxifloxacin.
MYCOPHENOLATE
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Phenylbutazone.
Mycophenolate Mofetil
The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Phenylbutazone.
Mycophenolic Acid
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Phenylbutazone.
Nabilone
The metabolism of Phenylbutazone can be decreased when combined with Nabilone.
Nabumetone
The risk or severity of adverse effects can be increased when Nabumetone is combined with Phenylbutazone.
Nadolol
Phenylbutazone may decrease the antihypertensive activities of Nadolol.
Nadroparin
Phenylbutazone may increase the anticoagulant activities of Nadroparin.
Naftifine
The risk or severity of adverse effects can be increased when Naftifine is combined with Phenylbutazone.
Nalidixic Acid
Phenylbutazone may increase the neuroexcitatory activities of Nalidixic Acid.
Naproxen
The risk or severity of adverse effects can be increased when Naproxen is combined with Phenylbutazone.
Nebivolol
Phenylbutazone may decrease the antihypertensive activities of Nebivolol.
Nefazodone
Nefazodone may increase the antiplatelet activities of Phenylbutazone.
Neomycin
Phenylbutazone may decrease the excretion rate of Neomycin which could result in a higher serum level.
Nepafenac
The risk or severity of adverse effects can be increased when Nepafenac is combined with Phenylbutazone.
Netilmicin
Phenylbutazone may decrease the excretion rate of Netilmicin which could result in a higher serum level.
Nicardipine
The metabolism of Phenylbutazone can be decreased when combined with Nicardipine.
Niflumic Acid
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Niflumic Acid.
Nimesulide
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Nimesulide.
Norfloxacin
Phenylbutazone may increase the neuroexcitatory activities of Norfloxacin.
Oenothera biennis seed extract
The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Phenylbutazone.
Ofloxacin
Phenylbutazone may increase the neuroexcitatory activities of Ofloxacin.
Olmesartan
The risk or severity of adverse effects can be increased when Olmesartan is combined with Phenylbutazone.
Olopatadine
The risk or severity of adverse effects can be increased when Olopatadine is combined with Phenylbutazone.
Olsalazine
The risk or severity of adverse effects can be increased when Olsalazine is combined with Phenylbutazone.
Omacetaxine Mepesuccinate
The risk or severity of bleeding can be increased when Phenylbutazone is combined with Omacetaxine mepesuccinate.
Omeprazole
The metabolism of Phenylbutazone can be decreased when combined with Omeprazole.
Oxaprozin
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Oxaprozin.
Oxprenolol
Phenylbutazone may decrease the antihypertensive activities of Oxprenolol.
Oxyphenbutazone
The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Phenylbutazone.
Palmidrol
The risk or severity of adverse effects can be increased when Palmidrol is combined with Phenylbutazone.
Pamidronate
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Pamidronate.
Pamidronic Acid
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Pamidronate.
Paramethasone
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Paramethasone.
Parecoxib
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Parecoxib.
Paromomycin
Phenylbutazone may decrease the excretion rate of Paromomycin which could result in a higher serum level.
Paroxetine
Paroxetine may increase the antiplatelet activities of Phenylbutazone.
Parthenolide
The risk or severity of adverse effects can be increased when Parthenolide is combined with Phenylbutazone.
Pefloxacin
Phenylbutazone may increase the neuroexcitatory activities of Pefloxacin.
Penbutolol
Phenylbutazone may decrease the antihypertensive activities of Penbutolol.
Pentaerythritol Tetranitrate
Phenylbutazone may increase the anticoagulant activities of Pentaerythritol Tetranitrate.
Pentosan Polysulfate
Phenylbutazone may increase the anticoagulant activities of Pentosan Polysulfate.
Perindopril
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Perindopril.
Phenindione
Phenylbutazone may increase the anticoagulant activities of Phenindione.
Phenobarbital
The metabolism of Phenylbutazone can be increased when combined with Phenobarbital.
Phenprocoumon
Phenylbutazone may increase the anticoagulant activities of Phenprocoumon.
Phenytoin
The metabolism of Phenylbutazone can be increased when combined with Phenytoin.
Pimecrolimus
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Phenylbutazone.
Pindolol
Phenylbutazone may decrease the antihypertensive activities of Pindolol.
Piretanide
The therapeutic efficacy of Piretanide can be decreased when used in combination with Phenylbutazone.
Pirfenidone
The risk or severity of adverse effects can be increased when Pirfenidone is combined with Phenylbutazone.
Piroxicam
The risk or severity of adverse effects can be increased when Piroxicam is combined with Phenylbutazone.
Piroxicam-Beta-Cyclodextrin
The risk or severity of adverse effects can be increased when Piroxicam is combined with Phenylbutazone.
Plazomicin
Phenylbutazone may decrease the excretion rate of Plazomicin which could result in a higher serum level.
Polyestradiol Phosphate
Phenylbutazone may increase the thrombogenic activities of Polyestradiol phosphate.
Polythiazide
The therapeutic efficacy of Polythiazide can be decreased when used in combination with Phenylbutazone.
Pomalidomide
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Pomalidomide.
Potassium Citrate
Phenylbutazone may increase the anticoagulant activities of Potassium Citrate.
Practolol
Phenylbutazone may decrease the antihypertensive activities of Practolol.
Pralatrexate
The serum concentration of Pralatrexate can be increased when it is combined with Phenylbutazone.
Prasterone
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Prasterone.
Prednicarbate
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Prednicarbate.
Prednisolone
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Prednisolone.
Prednisone
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Prednisone.
Pregnenolone
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Pregnenolone.
Primidone
The metabolism of Phenylbutazone can be increased when combined with Primidone.
Probenecid
The serum concentration of Phenylbutazone can be increased when it is combined with Probenecid.
Promestriene
Phenylbutazone may increase the thrombogenic activities of Promestriene.
Propafenone
Phenylbutazone may decrease the antihypertensive activities of Propafenone.
Propranolol
Phenylbutazone may decrease the antihypertensive activities of Propranolol.
protein C, human
Phenylbutazone may increase the anticoagulant activities of Protein C.
protein S, human
Phenylbutazone may increase the anticoagulant activities of Protein S human.
Protocatechualdehyde
Phenylbutazone may increase the anticoagulant activities of Protocatechualdehyde.
Pyrimethamine
The metabolism of Phenylbutazone can be decreased when combined with Pyrimethamine.
Quinapril
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Quinapril.
Quinestrol
Phenylbutazone may increase the thrombogenic activities of Quinestrol.
Quinethazone
The therapeutic efficacy of Quinethazone can be decreased when used in combination with Phenylbutazone.
Quinine
The metabolism of Phenylbutazone can be decreased when combined with Quinine.
Ramipril
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Ramipril.
Rescinnamine
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Rescinnamine.
Resveratrol
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Resveratrol.
Reviparin
Phenylbutazone may increase the anticoagulant activities of Reviparin.
Reviparin sodium
Phenylbutazone may increase the anticoagulant activities of Reviparin.
Rifampin
The metabolism of Phenylbutazone can be increased when combined with Rifampicin.
Rifapentine
The metabolism of Phenylbutazone can be increased when combined with Rifapentine.
Rilpivirine
The serum concentration of Rilpivirine can be decreased when it is combined with Phenylbutazone.
Rimexolone
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Rimexolone.
Risedronate
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Risedronate.
Risedronic Acid
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Risedronate.
Rivaroxaban
Phenylbutazone may increase the anticoagulant activities of Rivaroxaban.
Rofecoxib
The risk or severity of adverse effects can be increased when Rofecoxib is combined with Phenylbutazone.
Rosoxacin
Phenylbutazone may increase the neuroexcitatory activities of Rosoxacin.
Rucaparib
The metabolism of Phenylbutazone can be decreased when combined with Rucaparib.
Sacubitril
The risk or severity of adverse effects can be increased when Sacubitril is combined with Phenylbutazone.
Salicylamide
The risk or severity of adverse effects can be increased when Salicylamide is combined with Phenylbutazone.
Salicylic Acid
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Salicylic acid.
Salsalate
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Salsalate.
Saralasin
The risk or severity of adverse effects can be increased when Saralasin is combined with Phenylbutazone.
Sarilumab
Sarilumab may increase the immunosuppressive activities of Phenylbutazone.
Saxagliptin
The serum concentration of Saxagliptin can be decreased when it is combined with Phenylbutazone.
Saxagliptin Anhydrous
The serum concentration of Saxagliptin can be decreased when it is combined with Phenylbutazone.
Secobarbital
The metabolism of Phenylbutazone can be increased when combined with Secobarbital.
Serratiopeptidase
The risk or severity of adverse effects can be increased when Serrapeptase is combined with Phenylbutazone.
Sertraline
Sertraline may increase the antiplatelet activities of Phenylbutazone.
Sildenafil
The metabolism of Phenylbutazone can be decreased when combined with Sildenafil.
Sisomicin
Phenylbutazone may decrease the excretion rate of Sisomicin which could result in a higher serum level.
Sodium Citrate
Phenylbutazone may increase the anticoagulant activities of Sodium Citrate.
Sodium Phosphate
Sodium phosphate may increase the nephrotoxic activities of Phenylbutazone.
Sodium Phosphate, Monobasic
Sodium phosphate may increase the nephrotoxic activities of Phenylbutazone.
SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS
Sodium phosphate may increase the nephrotoxic activities of Phenylbutazone.
Sorafenib
The metabolism of Phenylbutazone can be decreased when combined with Sorafenib.
Sotalol
Phenylbutazone may decrease the antihypertensive activities of Sotalol.
Sparfloxacin
Phenylbutazone may increase the neuroexcitatory activities of Sparfloxacin.
Spirapril
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Spirapril.
Spironolactone
Phenylbutazone may decrease the antihypertensive activities of Spironolactone.
Streptomycin
Phenylbutazone may decrease the excretion rate of Streptomycin which could result in a higher serum level.
Sulfadiazine
The metabolism of Phenylbutazone can be decreased when combined with Sulfadiazine.
Sulfamethoxazole
The metabolism of Phenylbutazone can be decreased when combined with Sulfamethoxazole.
Sulfasalazine
The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Phenylbutazone.
Sulfisoxazole
The metabolism of Phenylbutazone can be decreased when combined with Sulfisoxazole.
Sulindac
The risk or severity of adverse effects can be increased when Sulindac is combined with Phenylbutazone.
Suprofen
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Suprofen.
synthetic conjugated estrogens, A
Phenylbutazone may increase the thrombogenic activities of Synthetic Conjugated Estrogens, A.
synthetic conjugated estrogens, B
Phenylbutazone may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B.
Tacrolimus
Phenylbutazone may increase the nephrotoxic activities of Tacrolimus.
Tafluprost
The therapeutic efficacy of Tafluprost can be decreased when used in combination with Phenylbutazone.
Talinolol
Phenylbutazone may decrease the antihypertensive activities of Talinolol.
Talniflumate
The risk or severity of adverse effects can be increased when Talniflumate is combined with Phenylbutazone.
Technetium Tc 99m Medronate
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Technetium Tc-99m medronate.
Telmisartan
The risk or severity of adverse effects can be increased when Telmisartan is combined with Phenylbutazone.
Temafloxacin
Phenylbutazone may increase the neuroexcitatory activities of Temafloxacin.
Tenofovir Disoproxil
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Tenofovir disoproxil.
Tenoxicam
The risk or severity of adverse effects can be increased when Tenoxicam is combined with Phenylbutazone.
Terbutaline
Phenylbutazone may decrease the antihypertensive activities of Terbutaline.
Terbutaline Sulfate
Phenylbutazone may decrease the antihypertensive activities of Terbutaline.
Teriflunomide
The risk or severity of adverse effects can be increased when Teriflunomide is combined with Phenylbutazone.
Tertatolol
Phenylbutazone may decrease the antihypertensive activities of Tertatolol.
Tiaprofenic Acid
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Tiaprofenic acid.
Tibolone
Phenylbutazone may increase the thrombogenic activities of Tibolone.
Ticagrelor
The metabolism of Phenylbutazone can be decreased when combined with Ticagrelor.
Ticlopidine
The metabolism of Phenylbutazone can be decreased when combined with Ticlopidine.
Tiludronate
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Tiludronic acid.
Tiludronic Acid
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Tiludronic acid.
Timolol
Phenylbutazone may decrease the antihypertensive activities of Timolol.
Timolol Anhydrous
Phenylbutazone may decrease the antihypertensive activities of Timolol.
Tixocortol
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Tixocortol.
Tobramycin
Phenylbutazone may decrease the excretion rate of Tobramycin which could result in a higher serum level.
Tolbutamide
The metabolism of Phenylbutazone can be decreased when combined with Tolbutamide.
Tolfenamic Acid
The risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Phenylbutazone.
Tolmetin
The risk or severity of adverse effects can be increased when Tolmetin is combined with Phenylbutazone.
Torsemide
The therapeutic efficacy of Torasemide can be decreased when used in combination with Phenylbutazone.
Trandolapril
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Trandolapril.
Tranilast
The risk or severity of adverse effects can be increased when Tranilast is combined with Phenylbutazone.
Travoprost
The therapeutic efficacy of Travoprost can be decreased when used in combination with Phenylbutazone.
Treprostinil
The risk or severity of adverse effects can be increased when Treprostinil is combined with Phenylbutazone.
Triamcinolone
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Triamcinolone.
Triamterene
Phenylbutazone may decrease the antihypertensive activities of Triamterene.
Tribenoside
The risk or severity of adverse effects can be increased when Tribenoside is combined with Phenylbutazone.
Trichlormethiazide
The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Phenylbutazone.
Trimethoprim
The metabolism of Phenylbutazone can be decreased when combined with Trimethoprim.
Trisodium Citrate Anhydrous
Phenylbutazone may increase the anticoagulant activities of Sodium Citrate.
Trolamine Salicylate
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Trolamine salicylate.
Trovafloxacin
Phenylbutazone may increase the neuroexcitatory activities of Trovafloxacin.
Troxerutin
Phenylbutazone may increase the anticoagulant activities of Troxerutin.
UNOPROSTONE
The therapeutic efficacy of Unoprostone can be decreased when used in combination with Phenylbutazone.
Valdecoxib
The risk or severity of adverse effects can be increased when Valdecoxib is combined with Phenylbutazone.
Valproate
The metabolism of Phenylbutazone can be decreased when combined with Valproic Acid.
Valproic Acid
The metabolism of Phenylbutazone can be decreased when combined with Valproic Acid.
Valsartan
The metabolism of Phenylbutazone can be decreased when combined with Valsartan.
Vancomycin
The serum concentration of Vancomycin can be increased when it is combined with Phenylbutazone.
Venlafaxine
Venlafaxine may increase the antiplatelet activities of Phenylbutazone.
Voriconazole
The metabolism of Phenylbutazone can be decreased when combined with Voriconazole.
Warfarin
Phenylbutazone may increase the anticoagulant activities of Warfarin.
Zafirlukast
The metabolism of Phenylbutazone can be decreased when combined with Zafirlukast.
Zileuton
The risk or severity of adverse effects can be increased when Zileuton is combined with Phenylbutazone.
Zofenopril
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Zofenopril.
Zoledronic Acid
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Zoledronic acid.
Zoledronic Acid Anhydrous
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Zoledronic acid.
Zomepirac
The risk or severity of adverse effects can be increased when Zomepirac is combined with Phenylbutazone.
